Waldencast plc
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Waldencast
Perfumes, Cosmetics & Other Toilet Preparations, SIC 2844
Waldencast plc operates a global multi-brand platform focused on developing, acquiring, and scaling beauty and wellness brands. The company conducts business through two primary operating segments: Obagi Medical and Milk Makeup. The Obagi Medical segment develops and markets medical-grade skincare, aesthetic solutions, and hyaluronic acid injectable fillers, catering to physicians, dermatologists, plastic surgeons, medical spas, and consumers via e-commerce and retail channels. The Milk Makeup segment offers clean, vegan, and cruelty-free prestige color cosmetics and skincare items, which appeal strongly to younger consumers and are distributed primarily through specialty beauty retailers and online storefronts.
The company distributes its products across more than 95 countries for Obagi Medical, with key markets spanning North America, Europe, Asia, and Latin America. Waldencast operates facilities across multiple leased properties, including offices, in-house studios, and warehouse space in the United States and the United Kingdom. Waldencast plc maintains its principal executive office in London, United Kingdom.
Summary of the business section of Waldencast's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Waldencast plc
- Founded
- 2020
- Headquarters
- London, X0
- Address
- 81 Fulham Road SW3 6RD
- Phone
- 44 (0)20 3196 0264
- Website
- waldencast.com
- Employees
- 248, Dec 31, 2025
- Industry
- Perfumes, Cosmetics & Other Toilet Preparations
- Auditor
- Deloitte & Touche LLP, Costa Mesa, California
Stock & identifiers
- Ticker
- MLKMF
- Other tickers
- MLKWF
- Exchange
- OTC
- IPO date
- Mar 17, 2021
- Shares outstanding
- 128M, Dec 31, 2025
- Public float
- $385.46M, Jun 30, 2021
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 1840199
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michel Brousset | Chief Executive Officer, Director | 3,801,199 |
| Hind Sebti | Chief Growth Officer, Director | 507,434 |
| Manuel Manfredi | Chief Financial Officer | 118,933 |
| Cristiano Souza | Director | 12,587,580 |
| Aaron Chatterley | Director | 57,453 |
| Kelly Brookie | Director | 37,454 |
| Motta Roberto Moses Thompson | Director | 118,727 |
| Juliette Hickman | Director | 80,952 |
| Felipe Dutra | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, Obagi Medical had 248 employees and all non-unionized.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 15, 2026 | Deregistration | Termination of SEC registration (Form 15) |
| Sep 24, 2026 | Delisting | Notice of delisting from exchange (Form 25) |
| May 2, 2023 | Late filing | Notification of late filing |
| Jul 27, 2022 | Delisting | Notice of delisting from exchange (Form 25) |
| Jul 27, 2022 | Name change | Name changed from Waldencast Acquisition Corp. to Waldencast plc |
| Feb 14, 2022 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Nov 15, 2021 | Late filing | Notification of late filing |
| May 28, 2021 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 17, 2021 | Late filing | Notification of late filing |
| Mar 17, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 12, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |